Feng, Xiaoshuang
Zhang, Yiwen http://orcid.org/0000-0002-1193-2263
Vaselkiv, J. Bailey
Li, Ruifeng
Nguyen, Paul L.
Penney, Kathryn L.
Giovannucci, Edward L. http://orcid.org/0000-0002-6123-0219
Mucci, Lorelei A.
Stopsack, Konrad H. http://orcid.org/0000-0002-0722-1311
Funding for this research was provided by:
Prostate Cancer Foundation
Zhu Family Center for Global Cancer Prevention
American Cancer Society (CRP-23-1014041)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R03 CA226942)
Article History
Received: 19 April 2023
Revised: 6 October 2023
Accepted: 17 October 2023
First Online: 28 October 2023
Competing interests
: KLP reports research grants/funding from Janssen. PLN reports research funding from Astellas, Bayer, and Janssen; consulting for Nanocan, Boston Scientific, Bayer, Janssen, Novartis, and Blue Earth; and equity in Nanocan. LAM reports grants/funding from Bayer, AstraZeneca, and Janssen; has provided expert testimony for Bayer. The remaining authors declare no competing interests.
: The study protocol was approved by the institutional review board at the Harvard T.H. Chan School of Public Health, and participating cancer registries, as required.
: Not applicable.